Loading...
Loading...
MTP| Name | Value |
|---|---|
| Revenues | 615.0K |
| Cost of Revenue | -580.5K |
| Gross Profit | 1,195.5K |
| Operating Expense | 3,831.5K |
| Operating I/L | 8,940.5K |
| Other Income/Expense | -11.0K |
| Interest Income | 0.0K |
| Pretax | 8,929.5K |
| Income Tax Expense | 219.5K |
| Net Income/Loss | 8,710.0K |
Midatech Pharma plc is a UK-based drug delivery technology company specializing in the research and development of innovative medicines. The company's revenue is generated through the development of various treatments, including MTX110 for brain tumors, MTX114 for psoriasis, MTD211 for schizophrenia and major depressive disorder, and MTD219 for organ transplant rejection. Additionally, Midatech Pharma offers drug delivery platforms like Q-Sphera for sustained release, MidaSolve for solubilizing drugs, and MidaCore for targeted therapy. These products and platforms form the core of the company's business, driving its growth and success in the pharmaceutical industry.
